

Facilitating Biomarker Development and Qualification: Strategies for Prioritization, Data-Sharing, and Stakeholder Collaboration

Embassy Suites - Convention Center • Washington, DC

October 27, 2015

Participant List

Jeff Allen

Executive Director, Friends of Cancer Research

Anna Barker

Director, National Biomarker Development Alliance (NBDA), Co-Director, Complex Adaptive Systems Initiative, Professor, School of Life Sciences, Arizona State University

Robert Becker

Chief Medical Officer, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Linda Brady

Director, Division of Neuroscience and Basic Behavioral Science, National Institute of Mental Health, National Institutes of Health

Steve Broadbent

Chief Operating Officer and Executive Director, Polycystic Kidney Disease Outcomes Consortium, Critical Path Institute

Martha Brumfield

President and Chief Executive Officer, Critical Path Institute

ShaAvhrée Buckman-Garner

Director, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Robert Califf

Deputy Commissioner, Office of Medical Products and Tobacco, U.S. Food and Drug Administration

Aloka Chakravarty

Director, Division of Biometrics, Office of Biostatistics, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Barb Conley

Associate Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health

Greg Daniel

Managing Director for Evidence Development & Innovation, Center for Health Policy and Fellow, Economic Studies, The Brookings Institution

Volker Fischer

Vice President, Drug Metabolism and Pharmacokinetics, AbbVie

Amanda Grimm

Manager, Federal Policy, Cystic Fibrosis Foundation

Marian Hajduch

Chair, Board of National Directors EATRIS-ERIC (European Infrastructure for Translational Medicine), Director, Institute of Molecular and Translational Medicine, Palacky University, Czech Republic

Holli Hamilton

Senior Medical Officer, Division of Extramural Research, National Center for Advancing Translational Sciences, National Institutes of Health

Gary Herman

Vice President, Early Clinical Development, Regeneron

Steve Hoffmann

Scientific Program Manager, Foundation for the National Institutes of Health

Paul Howard

Senior Fellow and Director, Health Policy, Manhattan Institute for Policy Research

Lynn Hudson

Chief Science Officer, Critical Path Institute

Nina Hunter

Special Assistant for Medical Policy, Office of Medical Products and Tobacco, U.S. Food and Drug Administration

Ilan Irony

Chief, General Medicine Branch, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Robert Johnson

Director, Office of Regulatory Affairs, Acting Director, Office of Clinical Research Resources, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Gary Kelloff

Special Advisor, National Cancer Institute, National Institutes of Health

Sean Khozin

Senior Medical Officer, Division of Oncology Products II, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Rebecca Kush

President and Chief Executive Officer, Clinical Data Interchange Standards Consortium

Gabriela Lavezzari

Assistant Vice President, Science & Regulatory Advocacy, Pharmaceutical Research and Manufacturers of America

John Lawrence

Mathematician, Division of Biostatistics I, Office of Biostatistics, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Christopher Leptak

Biomarker and Companion Diagnostic Lead, Co-Director, Biomarker Qualification Program, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Mark McClellan

Senior Fellow and Director, Health Care Innovation and Value Initiative, The Brookings Institution

Scott McGoohan

Director, Science and Regulatory Affairs, Biotechnology Industry Organization

Pamela McInnes

Deputy Director, National Center for Advancing Translational Sciences, National Institutes of Health

Lisa McShane

Mathematical Statistician, National Cancer Institute, National Institutes of Health

Waseem Nosair

Research Assistant, Center for Health Policy, The Brookings Institution

Katie O'Callaghan

Associate Center Director, Science & Strategic Partnerships, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Michael Pacanowski

Associate Director for Genomics and Targeted Therapy, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Elektra Papadopoulos

Acting Associate Director Clinical Outcome Assessments Staff, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Scott Patterson

Vice President, Biomarker Sciences, Gilead Sciences, Inc.

Ronald Perrone

Associate Chief, Division of Nephrology
Tufts Medical Center, Professor of Medicine,
Tufts University School of Medicine

David Reese

Senior Vice President, Translational Sciences,
Amgen Inc.

Peter Revill

Director of Biology Content, Thomson Reuters

Elizabeth Richardson

Research Associate, Center for Health Policy,
The Brookings Institution

Melissa Robb

Associate Director for Regulatory Affairs, Office of
Medical Policy, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration

Mark Rogge

Global Head of Clinical Pharmacology, Early Clinical
Development, Biogen

Laura Rosema

AAAS Science and Technology Policy Fellow, Office
of Science Policy, Office of the Director, National
Institutes of Health

John-Michael Sauer

Executive Director, Predictive Safety Testing
Consortium, Critical Path Institute

Nathalie Seigneuret

Senior Scientific Project Manager, Innovative
Medicines Initiative

Frank Sistare

Associate Vice President, Investigative Laboratory
Sciences Safety Assessment and Laboratory Animal
Resources, Merck

Lana Skirboll

Vice President, Scientific and Academic Affairs,
Sanofi

Jacqueline Tarrant

Senior Scientist-Pathologist,
Genentech

Robert Temple

Deputy Director for Clinical Science, Center for Drug
Evaluation and Research, U.S. Food and Drug
Administration

Aliza Thompson

Clinical Team Leader, Division of Cardiovascular and
Renal Products, Center for Drug Evaluation and
Research, U.S. Food and Drug Administration

John Wagner

Senior Vice President, Head of Clinical and
Translational Sciences, Takeda Pharmaceuticals Co.

John Walsh

President, COPD Foundation

Sue-Jane Wang

Associate Director, Office of Biostatistics, Office of
Transnational Sciences, Center for Drug Evaluation
and Research, U.S. Food and Drug Administration

Paul Watkins

Director, The Hamner – UNC Institute for Drug
Safety Sciences, Professor of Medicine, Pharmacy,
and Public Health at the University of North
Carolina at Chapel Hill

David Wholley

Director, Research Partnerships,
Foundation for the National Institutes of Health

Janet Woodcock

Director, Center for Drug Evaluation and Research,
U.S. Food and Drug Administration